ABBISKO-B(02256): BEJEMAI Receives FDA Approval for the Treatment of TGCT
ABBISKO-B (02256) announced that on November 11, 2026, the company's subsidiary Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Therapeutics) announced that BEJEMAI (English trade name: PIMJETMI; generic name: pimicotinib hydrochloride capsules), a CSF-1R small molecule inhibitor, has received approval from the U.S. Food and Drug Administration (FDA) for the systemic treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection may result in worsening functional limitation or severe complications.
ABBISKO-B(02256) announced that on November 11, 2026, the company's subsidiary Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko) announced that BEJEMAI (English trade name: PIMJETMI, generic name: pimicotinib hydrochloride capsules), a CSF-1R small molecule inhibitor, has received approval from the U.S. Food and Drug Administration (FDA) for the systemic treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection may result in worsening functional limitation or severe complications.
Related Articles
BEKE-W (02423) repurchased approximately 248,600 shares for about US$1.5 million on November 10.
CALC (01848) issues 7.8723 million shares under scrip dividend scheme
TEXWINCA HOLD (00321) announces interim results: profit attributable to ordinary equity holders approximately HK$54 million, down 51.8% year-on-year.
BEKE-W (02423) repurchased approximately 248,600 shares for about US$1.5 million on November 10.
CALC (01848) issues 7.8723 million shares under scrip dividend scheme
TEXWINCA HOLD (00321) announces interim results: profit attributable to ordinary equity holders approximately HK$54 million, down 51.8% year-on-year.
